Scientific and Regulatory Policy Committee Points to Consider for Medical Device Implant Site Evaluation in Nonclinical Studies

• Published in: Toxicologic pathology 2022-06, Vol.50 (4), p.512-530
• Main Authors: O’Brien, Maureen T., Schuh, JoAnn C. L., Wancket, Lyn M., Cramer, Sarah D., Funk, Kathleen A., Jackson, Nicolette D., Kannan, Kamala, Keane, Kevin, Nyska, Abraham, Rousselle, Serge D., Schucker, Adrienne, Thomas, Valerie S., Tunev, Stefan
• Format: Article
• Language: English
• ISSN: 0192-6233; 1533-1601
• DOI: 10.1177/01926233221103202

Nonclinical implantation studies are a common and often critical step for medical device safety assessment in the bench-to-market pathway. Nonclinical implanted medical devices or drug-device combination products require complex macroscopic and microscopic pathology evaluations due to the physical presence of the device itself and unique tissue responses to device materials. The Medical Device Implant Site Evaluation working group of the Society of Toxicologic Pathology’s (STP) Scientific and Regulatory Policy Committee (SRPC) was tasked with reviewing scientific, technical, and regulatory considerations for these studies. Implant site evaluations require highly specialized methods and analytical schemes that should be designed on a case-by-case basis to address specific study objectives. Existing STP best practice recommendations can serve as a framework when performing nonclinical studies under Good Laboratory Practices and help mitigate limitations in standards and guidances for implant evaluations (e.g., those from the International Organization for Standardization [ISO], ASTM International). This article integrates standards referenced by sponsors and regulatory bodies with practical pathology evaluation methods for implantable medical devices and combination products. The goal is to ensure the maximum accuracy and scientific relevance of pathology data acquired during a medical device or combination drug-device implantation study.